孕妇对产前呼吸道合胞病毒疫苗的认知与接种情况——明尼苏达州,2023-2024年
2023年9月至11月对1999名孕12-30周的孕妇开展在线调查,455人参与(应答率23%),65%打算接种RSV疫苗;在427名符合条件者中51%已接种。感知疫苗有效性和医务人员推荐与接种意愿及接种率均相关。
要点
- 65%的受访孕妇打算接种RSV疫苗,符合条件者中51%实际接种。
- 感知疫苗有效性与接种意愿及接种率均相关。
- 医务人员推荐与接种意愿及接种率均相关。
核心结论
- 医务人员强烈推荐孕期接种RSV疫苗并纳入疫苗安全性和有效性信息,可能提高接种率。
研究设计与样本
- 邀请1999名≥18岁、孕12-30周且在HealthPartners接受产前保健的孕妇于2023年9月至11月完成在线调查。
- 评估孕32-36周患者在2023年10月12日至2024年2月1日期间的RSV疫苗接种情况。
- 使用泊松回归估计调整患病率比(aPR)和调整率比(aRR)及95%CI,调整年龄、种族、民族、医疗补助、与≤5岁儿童同住及从事医疗工作,并按调查参与逆概率加权。
主要发现
- 455名患者参与(应答率23%),26%为非白人和/或西班牙裔,46%与≤5岁儿童同住,30%从事医疗工作;65%打算孕期接种RSV疫苗。
- 427名符合条件的受访者中,51%已接种RSV疫苗。
- 感知疫苗有效性与接种意愿相关(aPR 19.47,95%CI 5.82-65.12),与接种率相关(aRR 3.06,95%CI 1.70-5.51)。
- 医务人员推荐与接种意愿相关(aPR 8.04,95%CI 4.23-15.29),与接种率相关(aRR 3.30,95%CI 1.99-5.48)。
- 不打算接种RSV疫苗者的回答提示存在安全性担忧。
临床怎么用
- 作者认为,医务人员强烈推荐孕期接种RSV疫苗并纳入疫苗安全性和有效性信息,可能提高接种率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus (RSV) vaccine was recommended for use during pregnancy in September 2023. OBJECTIVE: To assess pregnant persons' intentions to receive and evaluate factors associated with RSV vaccine intentions and uptake. STUDY DESIGN: We invited 1999 pregnant persons ≥18 years, between 12 and 30 weeks gestation who had received prenatal care at HealthPartners to complete an online survey during September-November 2023. Our primary outcome was intention to receive RSV vaccine. We also asked respondents about reasons to or not to receive RSV vaccine and intentions to receive other vaccines during pregnancy. We assessed RSV vaccine uptake for patients 32-36 weeks gestation between 10/12/23 (first RSV vaccine in study population) and 2/1/24. We estimated adjusted prevalence ratios (aPR) and 95 % confidence intervals (CI) between responses and intention to receive RSV vaccination and, for those eligible to receive RSV vaccine, adjusted rate ratios (aRR) and 95 % CIs for RSV vaccine uptake. We adjusted aPRs and aRRs for age, race, ethnicity, Medicaid, living with children ≤5 years, and work in healthcare and weighted by inverse probability of survey participation using Poisson regression with robust variance. RESULTS: 455 patients participated (23 % response), 26 % were non-white and/or Hispanic, 46 % lived with children ≤5 years, and 30 % work in healthcare; 65 % intended to receive RSV vaccine during pregnancy. Among 427 eligible respondents, 51 % received RSV vaccine. Factors associated with RSV vaccination intention and uptake included perceived vaccine effectiveness (aPR: 19.47, 95 % CI: 5.82, 65.12; aRR 3.06, 95 % CI: 1.70, 5.51) and a provider recommendation (aPR: 8.04, 95 % CI: 4.23, 15.29; aRR 3.30, 95 % CI: 1.99, 5.48). Among those not planning to receive RSV vaccine, responses suggested safety concerns. CONCLUSION: Strong recommendations for receiving RSV vaccine during pregnancy from a healthcare provider incorporating information about RSV vaccine safety and effectiveness may increase vaccine uptake.
引用
- DeSilva MB, Vazquez-Benitez G, Seburg EM, et al. Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024. Vaccine. 2025. PMID: 40056807. doi:10.1016/j.vaccine.2025.126958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。